Courtney Ackeifi

Courtney Ackeifi

Auto-generated profile, based on publicly available information

Courtney Ackeifi

Breakthrough T1D, New York, New York, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Cell Stem Cell
Verified
Journal Article
Closed access
YYYin M. Yang
Yin M. Yang
SGShailesh K. Gupta
Shailesh K. Gupta
KKKevin J. Kim
Kevin J. Kim
BPBerit E. Powers
Berit E. Powers
ACAntonio Cerqueira
Antonio Cerqueira
LRLee L. Rubin
Lee L. Rubin

1 March 2019 in Cell Metabolism
Verified
Journal Article
Closed access
PWPeng Wang
Peng Wang
EKEsra Karakose
Esra Karakose
HLHongtao Liu
Hongtao Liu
ESEthan Swartz
Ethan Swartz
CACourtney Ackeifi
Courtney Ackeifi
ASAndrew F. Stewart
Andrew F. Stewart

12 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
CACourtney Ackeifi
Courtney Ackeifi
PWPeng Wang
Peng Wang
EKEsra Karakose
Esra Karakose
JFJocelyn E. Manning Fox
Jocelyn E. Manning Fox
BGBryan J. González
Bryan J. González
ASAndrew F. Stewart
Andrew F. Stewart
GLP-1 receptor agonists, widely used to treat diabetes, are converted to human β cell regenerative drugs by adding a DYRK1A inhibitor.

16 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
CACourtney Ackeifi
Courtney Ackeifi
ESEthan Swartz
Ethan Swartz
KKKunal Kumar
Kunal Kumar
HLHongtao Liu
Hongtao Liu
SCSuebsuwong Chalada
Suebsuwong Chalada
PWPeng Wang
Peng Wang
Small molecule inhibitors of dual specificity, tyrosine phosphorylation-regulated kinase 1A (DYRK1A), including harmine and others, are able to drive human β cell regeneration. While DYRK1A is certainly a target of this class, whether it is the only or the most important target is uncertain. Here, we employ a combined pharmacologic and genetic approach to refine the potential mitogenic targets of the DYRK1A inhibitor family in human islets. A combination of human β cell RNA sequencing, DYRK1A inhibitor kinome screens, pharmacologic inhibitors, and targeted silencing of candidate genes confirms that DYRK1A is a central target. Surprisingly, however, DYRK1B also proves to be an important target: silencing DYRK1A results in an increase in DYRK1B. Simultaneous silencing of both DYRK1A and DYRK1B yields greater β cell proliferation than silencing either individually. Importantly, other potential kinases, such as the CLK and the GSK3 families, are excluded as important harmine targets. Finally, we describe adenoviruses that are able to silence up to 7 targets simultaneously. Collectively, we report that inhibition of both DYRK1A and DYRK1B is required for induction of maximal rates of human β cell proliferation, and we provide clarity for future efforts in structure-based drug design for human β cell regenerative drugs.

16 May 2018 in Diabetologia
Verified
Journal Article
Closed access
PDF file
EKEsra Karakose
Esra Karakose
CACourtney Ackeifi
Courtney Ackeifi
PWPeng Wang
Peng Wang
ASAndrew F. Stewart
Andrew F. Stewart

9 February 2011 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
CTChristina M. Tognoni
Christina M. Tognoni
JCJr. Joseph G. Chadwick
Jr. Joseph G. Chadwick
CACourtney A. Ackeifi
Courtney A. Ackeifi
MTMarc Tetel
Marc Tetel
Background/Aims: The steroid hormones, including estradiol (E) and progesterone, act in the brain to regulate female reproductive behavior and physiology. These hormones mediate many of their biological effects by binding to their respective intracellular receptors. The receptors for estrogens (ER) and progestins (PR) interact with nuclear receptor coactivators to initiate transcription of steroid-responsive genes. Work from our laboratory and others reveals that nuclear receptor coactivators, including steroid receptor coactivator-1 (SRC-1) and SRC-2, function in brain to modulate ER-mediated induction of the PR gene and hormone-dependent behaviors. In order for steroid receptors and coactivators to function together, both must be expressed in the same cells. Methods: Triple-label immunofluorescence was used to determine if E-induced PR cells also express SRC-1 or SRC-2 in reproductively relevant brain regions of the female mouse. Results: The majority of E-induced PR cells in the medial preoptic area (61%), ventromedial nucleus of the hypothalamus (63%) and arcuate nucleus (76%) coexpressed both SRC-1 and SRC-2. A smaller proportion of PR cells expressed either SRC-1 or SRC-2, while a few PR cells expressed neither coactivator. In addition, compared to control animals, 17β-estradiol benzoate (EB) treatment increased SRC-1 levels in the arcuate nucleus, but not the medial preoptic area or the ventromedial nucleus of the hypothalamus. EB did not alter SRC-2 expression in any of the three brain regions analyzed. Conclusions: Taken together, the present findings identify a population of cells in which steroid receptors and nuclear receptor coactivators may interact to modulate steroid sensitivity in brain and regulate hormone-dependent behaviors in female mice. Given that cell culture studies reveal that SRC-1 and SRC-2 can mediate distinct steroid-signaling pathways, the present findings suggest that steroids can produce a variety of complex responses in these specialized brain cells.